scFv(CD38)-CD3zeta CAR-T Lentivirus

Chimeric antigen receptor T cell (CAR-T) therapy is a groundbreaking immunotherapy that harnesses the body''s own immune system to fight cancer. Developed in the early 21st century, CAR-T therapy involves genetically modifying T cells, a type of white blood cell that recognizes and eliminates infected or cancerous cells. In this approach, T cells are extracted from a patient''s blood and then genetically engineered in the laboratory to express a chimeric antigen receptor (CAR) that specifically targets cancer cells. This CAR enables the T cells to recognize and bind to specific antigens on the surface of tumor cells, thereby activating the tumor cells and causing them to proliferate. Once these modified T cells are re-infused into the patient, they actively seek out and eliminate cancer cells, demonstrating remarkable efficacy in treating certain hematological malignancies, such as acute lymphoblastic leukemia (ALL) and certain lymphomas.

CAR-T lentiviruses play a crucial role in the genetic engineering process for CAR-T cell production. Lentiviruses are a type of retrovirus that are uniquely suited for delivering genetic material into host cells, including T cells. The advantage of lentiviral vectors is their ability to stably integrate the target gene into the host cell genome, resulting in long-term expression of the CAR protein on the surface of T cells. In CAR-T therapy, lentiviral vectors are designed to carry the genetic instructions of CAR, which enables T cells to effectively recognize and attack cancer cells. This approach ensures that the modified T cells can proliferate and maintain their ability to target cancer for a long time, which is critical for sustained tumor treatment.